| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
The primary function of AI in the medical imaging industry is to analyze medical images like X-rays, CT scans, and MRIs with high precision and speed, detecting subtle abnormalities that might be missed by the human eye, thereby assisting in early disease detection and improving the accuracy of diagnoses, often by highlighting areas of concern for radiologists to further investigate.
|
Benefits of AI in Medical Imaging
Improved Accuracy and Precision |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Helps in scheduling patient visits |
|
According to the information provided, a key benefit of AI in radiology is its ability to improve diagnostic accuracy by identifying subtle abnormalities in medical images that might be missed by the human eye; essentially, enabling earlier detection of diseases through more thorough analysis of imaging data. |
AI in radiology: From promise to practice − A guide to effective integration |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
According to the article, "AI literacy" refers to the knowledge and skills needed to understand, evaluate, and use artificial intelligence (AI) technologies critically, including the ability to assess their reliability, accuracy, ethical implications, and potential biases, while also understanding how to effectively collaborate with AI systems in various contexts. |
A systematic review of AI literacy conceptualization, constructs, and implementation and assessment efforts (2019–2023) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
According to research, "hedonic motivation" is typically not listed as a significant factor influencing the acceptability of AI among healthcare professionals; meaning the pleasure or enjoyment derived from using AI technology is not a primary driver for healthcare professionals when deciding to adopt AI systems.
|
What factors contribute to the acceptance of artificial intelligence? A systematic review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
|
|
According to the article, social influence significantly impacts the acceptability of AI in healthcare by influencing an individual's perception of whether important others (like colleagues or peers) believe they should use AI technology, thereby shaping their trust and intention to adopt it within the healthcare setting; essentially, if people around them are positive about AI, they are more likely to view it favorably and consider using it themselves.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
None of the above |
|
A major perceived threat regarding AI usage in healthcare settings is the potential for biased diagnoses or treatment recommendations due to biases present in the training data used to develop the AI algorithms, which could lead to unequal treatment of certain patient demographics.
|
Promoting Healthcare Workers’ Adoption Intention of Artificial-Intelligence-Assisted Diagnosis and Treatment: The Chain Mediation of Social Influence and Human–Computer Trust |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Decreasing the cost of AI systems |
|
According to the article, to increase AI acceptability among medical professionals, it is essential to design "human-centered AI systems" that consider factors beyond just high algorithmic performance, including accessibility for users with different levels of AI literacy, compatibility with clinical workflow practices, and the broader institutional and cultural context of deployment.
|
Challenges and strategies for wide-scale artificial intelligence (AI) deployment in healthcare practices: A perspective for healthcare organizations |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The literature has converged towards three overarching categories of factors underpinning AI acceptability including: user factors involving trust, system understanding, AI literacy, and technology receptiveness; system usage factors entailing value proposition, self-efficacy, burden, and workflow integration |
Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Determines the pricing of AI systems |
|
Ethical considerations significantly influence the acceptability of AI among healthcare professionals, as they must be confident that AI systems are designed and implemented in a way that prioritizes patient well-being, respects privacy, avoids bias, and ensures transparency in decision-making, ultimately impacting their trust and willingness to use the technology in clinical practice; if ethical concerns are not adequately addressed, healthcare professionals may be hesitant to adopt AI due to potential risks to patient care and legal repercussions |
Ethical implications of AI and robotics in healthcare: A review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
|
Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
The primary objective of using human embryonic stem cells in treating Parkinson's disease is to replace the lost dopamine-producing neurons in the brain by guiding the stem cells to differentiate into functional neurons that can restore motor function affected by the disease; essentially aiming to alleviate symptoms and potentially slow the progression of Parkinson's by replenishing the damaged neural tissue. |
STEM CELL TREATMENTS IN THE FUTURE OF PARKINSON’S DISEASE MANAGEMENT |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
Rats were used to test the safety and efficacy of STEM-PD, a human embryonic stem cell (hESC) product for treating Parkinson's disease (PD).
|
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
6 months |
|
after the last dose. Overall there were no toxicologically meaningful drug-related animal findings associated with the long-term administration (6 months) of ceftriaxone. These results support safety of long-term use of ceftriaxone in human clinical trials. |
Preclinical Studies on the Pharmacokinetics, Safety and Toxicology of Oxfendazole: Toward First in Human Studies |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The clinical trial phase mentioned for STEM-PD is a Phase I/IIa clinical trial; this means it is a combined early-stage trial designed to assess both the safety and initial efficacy of the treatment in humans.
|
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Using random integration |
|
The STEM-PD product is manufactured using a "good manufacturing practice" (GMP) compliant protocol, where human embryonic stem cells are differentiated into dopamine progenitor cells, which are then cryopreserved to ensure consistency and facilitate shipment for clinical trials; this process allows for scalable production and rigorous quality control testing before being administered to patients in a clinical setting for Parkinson's disease treatment.
|
What is in the STEM-PD product and how does it work? |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
The product failed efficacy tests. |
|
According to the article, extensive safety studies in rats confirmed the safety of the STEM-PD product by demonstrating no adverse effects, tumor formation, or distribution to other parts of the body, even after long-term observation at the transplantation site; essentially proving the cells were safe and well-tolerated within the rat model. |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
No cells survived post-transplant. |
|
The key finding in the efficacy study of STEM-PD in rats was that the transplanted cells could reverse motor deficits in animal models of Parkinson's disease (PD).
|
What is in the STEM-PD product and how does it work?
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
The purity of STEM-PD batches is assessed using flow cytometry to measure the expression of specific markers, including FOXA2, OTX2, SOX1, PAX6, OCT3/4, and NANOG.
|
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are irrelevant to the process. |
|
Growth factors like FGF8b and SHH play a crucial role in the manufacturing process of STEM-PD (stem cell-derived Parkinson's disease neurons) by promoting the proliferation, survival, and differentiation of neural progenitor cells into dopamine-producing neurons, which are the primary cell type affected in Parkinson's disease; essentially guiding the stem cells to develop into the desired neuronal phenotype through complex signaling pathways during the differentiation stage of STEM-PD production.
|
Fibroblast growth factor 8: Multifaceted Role in Development and Developmental Disorder |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Development of new cognitive abilities |
|
which is measured as evidence of that pain state. Candidate analgesics are then evaluated for their effectiveness to reduce the pain behavior, and results are used to prioritize drugs for advancement to clinical testing. |
Core Outcome Measures in Preclinical Assessment of Candidate Analgesics |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|